Timothy C. Tyson, president and chief executive officer, said, "We are indebted to Dr. Lamon for his extraordinary efforts over the past three years. Kim took a strong discovery operation and added depth and muscle to our clinical development efforts. As he oversaw this remarkable strengthening of our research and development activities, Kim brought invaluable expertise at a critical time in our company's transformation. We also greatly appreciate that Kim stayed with us beyond his initial commitment and through the end of the VISER1 trial. We will miss Kim's leadership, but will continue to benefit from his counsel as a member of our scientific advisory board."
Dr. Lamon joined Valeant in 2002 as a member of its board of directors. He was appointed president, research and development, and chief scientific officer of Valeant in 2003, agreeing to lead the R&D unit for at least two years to help build a new management team and to progress a number of key projects.
Prior to joining Valeant, Dr. Lamon was the founder and president of SciPharma Consulting LLC. He has held senior research and clinical positions at Covance, Inc., Corning Clinical Laboratories, Corning Life Sciences, Inc., and Rhone Poulenc Rorer (now Aventis, Inc.).
About Valeant
Valeant Pharmaceuticals International (NYSE:VRX - News) is a global, science-based specialty pharmaceutical company that develops, manufactures and markets products primarily in the areas of neurology, infectious disease and dermatology. More information about Valeant can be found at www.valeant.com.
Viramidine is a registered trademark of Valeant Pharmaceuticals International or its related companies. All other trademarks are the trademarks or the registered trademarks of their respective owners.
Contact:
Valeant Pharmaceuticals Jeff Misakian, 714-545-0100, ext. 3309
Source: Valeant Pharmaceuticals
